Johnson & Johnson’s standout trial results for its Tecvayli and Darzalex Faspro pairing in previously treated relapsed or ...

A promising combination for multiple myeloma received FDA approval as a second-line therapy. The approval of teclistamab (Tecvayli) plus daratumumab hyaluronidase (Darzalex Faspro) stipulates use in ...

Clinical trial led by UAB researcher supports approval of new, potentially curative treatment for multiple myeloma ...

On Thursday, the U.S. Food and Drug Administration approved Johnson & Johnson‘s JNJ Tecvayli in combination with Darzalex ...

Awareness Month, which raises awareness, action, and amplifies the voices of individuals impacted by MM, a blood cancer in which abnormal plasma cells build up in the bone marrow, producing large ...

The management of smoldering multiple myeloma (MM) is undergoing a significant transformation, driven by growing evidence that early intervention can meaningfully delay progression to active disease.

Teclistamab plus daratumumab and hyaluronidase-fihj is approved for relapsed or refractory MM after one prior line of therapy, including a proteasome inhibitor and immunomodulatory agent.

For patients facing a multiple myeloma diagnosis, the journey is often defined by a search for the next line of defense. For survivor Julie Cohen, that search led her to the front lines of medical ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Johnson & Johnson has received approval from the U ...

Each year, approximately 36,000 people are diagnosed with the disease in the United States, according to the American Cancer ...

J&J has announced the US FDA approval for the combination of Tecvayli and Darzalex Faspro for adults with RRMM.

Rich's Myeloma Story For Rich, what started as nagging back pain and fatigue became impossible to ignore. He'd always been active and on the move, so when the ...